Dana-Farber Launches New Centers to Detect and Intercept Cancer
December 10th 2023Dana-Farber Cancer Institute is launching a first-of-its-kind, integrated clinic to increase early detection of precancerous conditions and to prevent cancer from arising in individuals at increased risk for the disease.
Read More
A drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results in a clinical trial involving patients with advanced neuroendocrine tumors, according to a study led by Dana-Farber Cancer Institute investigators.
Read More
Oncology Researchers Raise Ethics Concerns Posed By Patient-Facing Artificial Intelligence
November 13th 2023In a new paper in JCO Oncology Practice, bioethics researchers at Dana-Farber Cancer Institute call on medical societies, government leaders, clinicians, and researchers to work together to ensure AI-driven healthcare preserves patient autonomy and respects human dignity.
Read More
Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma, the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial.
Read More
Dana-Farber Cancer Institute, a Harvard Medical School affiliated teaching hospital and one of the world's leading cancer treatment and oncology research institutions, and Oncoclínicas & Co, the largest group dedicated to cancer in Latin America, announce the expansion of their collaboration with the opening of the first Oncoclínicas Cancer Center as an International Collaborative Member of Dana-Farber Cancer Institute.
Read More
Study Uncovers Function of Mysterious Disordered Regions of Proteins Implicated in Cancer
October 4th 2023New research from Dana-Farber Cancer Institute researcher Cigall Kadoch, PhD, along with colleagues at Princeton University and Washington University in St. Louis, reveals a key role for intrinsically disordered proteins known as IDRs that are implicated in a wide range of human diseases, from cancer to neurodegeneration
Read More
Deep Learning Reveals Valuable Clues About Kidney Cancer in Pathology Slides
September 25th 2023A team of Dana-Farber researchers has identified a potential new way to assess clinically valuable features of clear cell renal cell carcinoma, a form of kidney cancer, using image processing with deep learning.
Read More
A new agent that subverts myeloma cells from within while also subjecting them to an immune system attack produced impressive responses in combination with dexamethasone in patients with multiple myeloma that had relapsed and stopped responding to all currently available therapies
Read More
Researchers from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Medical University of Lodz have found a way to detect increased cancer risk associated with BRCA1 and BRCA2 mutations without genetic sequencing, according to a new study in Nature Communications.
Read More
Three-drug Combination Slows Progression of Advanced Kidney Cancer
May 16th 2023A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer Institute.
Read More
International Study Shows Many Younger Women with Breast Cancer Can Safely Have a Baby
May 9th 2023A new study published today in the New England Journal of Medicine found that for young women with hormone receptor-positive breast cancer, pausing endocrine therapy to pursue a pregnancy did not raise the short-term risk that the disease will recur.
Read More
Sox9 Protein Enables Molecular Time Travel That Can Lead to Colorectal Cancer
April 5th 2023Research from Dana-Farber Cancer Institute looks at what happens before the emergence of mutations that interrupt cellular differentiation in colorectal cancer and finds not only evidence of fetal reprogramming that can initiate cancer, but also a protein, Sox9, that fuels that reprogramming.
Read More
Novobiocin Attacks BRCA-Mutated Cancer Cells from Within and Without, Study Shows
March 31st 2023As the first clinical trial of the drug novobiocin is about to open for patients with cancers carrying BRCA gene mutations, new research at Dana-Farber Cancer Institute shows the drug poses a double threat to tumor cells.
Read More